Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis

Hepatology

Volumn 26, Issue 5, 1997, Pages 1123-1130

  Züchner, Dirk ^a   Sternsdorf, Thomas ^a   Szostecki, Carin ^a   Heathcote, E Jenny ^b   Cauch Dudek, Karen ^b   Will, Hans ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENTARY DNA; EPITOPE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BILIARY TRACT DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; KINETICS; MALE; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN LOCALIZATION;

EID: 0030670875     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1997.v26.pm0009362351     Document Type: Article

References (41)

1. Vierling JM. Primary biliary cirrhosis. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. 2nd ed. Philadelphia: Saunders, 1990:1158-1205.
2. Lozano F, Parés A, Borche L, Plana M, Gallart T, Rodés J, Vides J. Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis. HEPATOLOGY 1988;8:930-938.
3. Lassoued K, Brenard R, Degos F, Courvalin J-C, Andre C, Danon F, Brouet J-C, et al. Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis: a clinical and immunological study of a series of 150 patients with primary biliary cirrhosis. Gastroenterology 1990;99:181-186.
4. Bandin O, Courvalin J-C, Poupon R, Dubel T, Homberg JC, Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. HEPATOLOGY 1996;23:1020-1024.
5. Berg PA, Klein R. Immunology of primary biliary cirrhosis. Baillierers Clin Gastroenterol 1987;1:675-706.
6. Courvalin J-C, Lassoued K, Worman HJ, Blobel G. Identification and characterization of autoantibodies against nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med 1990; 172:961-996.
7. Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996;110:840-847.
8. Szostecki C, Guldner HH , Netter HJ, Will H. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recog-nized by autoantibodies from patients with primary biliary cirrhosis. J Immunol 1990;145:4338-4347.
9. Sternsdorf T, Guldner HH, Szostecki C, Grötzinger T, Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol 1995;42:257-268.
10. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, et al. Retinoic acid regulates aberrant nuclear localization of PML-RARa in acute promyelocytic leukemia cells. Cell 1994;76:345-356.
11. Lamond AI, Carmo-Fonseca M. The coiled body. Trends Cell Biol 1993; 3:198-204.
12. Ascoli CA, Maul GG. Identification of a novel nuclear domain. J Cell Biol 1991;112:785-795.
13. Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994;76:333-343.
14. Sternsdorf T, Grötzinger T, Jensen K, Will H. Nuclear dots: actors on many stages. Immunobiol 1997; in press.
15. Szostecki C, Krippner H, Penner E, Bautz FA. Autoimmune sera recognize a 100 kD nuclear protein antigen (Sp100). Clin Exp Immunol 1987;68:108-116.
16. Xie K, Lambie EJ, Snyder M. Nuclear dot antigens may specify transcriptional domains in the nucleus. Mol Cell Biol 1993;13:6170-6179.
17. Guldner HH, Szostecki C, Grötzinger T, Will H. IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J Immunol 1992; 149:4067-4073.
18. Lavau C, Marchio A, Fagioli M, Jansen J, Falini B, Lebon P, Grosveld F, et al. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 1995;11:871-876.
19. Grötzinger T, Sternsdorf T, Jensen K, Will H. Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Eur J Biochem 1996; 238:554-560.
20. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel putative transcribed locus. Nature 1990;347: 558-561.
21. Szostecki C, Guldner HH, Will H. Autoantibodies against nuclear dots in primary biliary cirrhosis. Semin Liver Dis 1997;17:71-78.
22. Szostecki C, Will H, Netter HJ, Guldner HH. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand J Immunol 1992;36:555-564.
23. Yoshikawa M, Tsujii T, Matsumara K, Yamao J, Matsumara Y, Kubo R, Fukui H, et al. Immunmodulatory effects of ursodeoxycholic acid on immune responses. HEPATOLOGY 1992;16:358-364.
24. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Micheletti P, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1994;19:1149-1156.
25. Lambert V, Fernholz D, Sprengel R, Fourel I, Deléage G, Wildner G, Trépo C, et al. Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S proteins. J Virol 1990;64: 1290-1297.
26. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promotors. Proc Natl Acad Sci U S A 1992;89:5547-5551.
27. Coppel RL, McNeilage LJ, Surh CD, van de Water J, Spithill TW, Wittingham S, Gershwin ME. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A 1988;85:7317-7321.
28. Fussey SPM, Guest JR, James OFW, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigenes in primary biliary cirrhosis. Proc Natl Acad Sci U S A 1988;85:8654-8658.
29. Surh CD, Danner DJ, Ahmed A, Coppel RL, Mackay IR, Dickson ER, Gershwin ME. Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA line of branched chain alpha-keto acid dehydrogenase dihydrolipoamide acetyltransferase, the 52 kD mitochondrial antigen. HEPATOLOGY 1989;9:63-68.
30. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;44:93-151.
31. Craft J, Mamula M, Ohosone Y, Boire G, Gold H, Hardin J. snRNPs and scRNPs as autoantigenes: clues to the etiology of the connective tissue disease. Clin Rheumatol 1990;9:10-19.
32. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994;13: 1073-1083.
33. Maul GG, Guldner HH, Spivack JG. Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J Gen Virol 1993;74:2679-2690.
34. Fregeau DR, Leung PSC, Coppel RL, McNeilage LJ, Medsger TA, Gershwin ME. Autoantibodies to mitochondria in systemic sclerosis. Arthritis Rheum 1988;31:386-392.
35. Nickowitz RE, Wozniak RW, Schaffner F, Worman HJ. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. Gastroenterology 1994;106:193-199.
36. Christensen E, Crowe J, Domiach D, Popper H, Ranek L, Rades J, Tygstrup N, et al. Clinical pattern and course of the disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980;78:236-246.
37. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. HEPATOLOGY 1990;1: 12-15.
38. Calmus Y, Guechot J, Podevin P, Bonnefis M-T, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-α production by monocytes. HEPATOLOGY 1992;16:719-723.
39. Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. HEPATOLOGY 1993;18:165-172.
40. Tanaka H, Makino Y, Miura T, Hirano F, Okamoto K, Komura K, Sato Y, et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. J Immunol 1996;156:1601-1608.
41. Kisand KE, Karvonen AL, Vuoristo M, Farkkila M, Lehtola J, Inkovaara J, Kisand KV, et al. Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis. J Mol Med 1996;74:269-274.